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Abstract
The therapeutic potential of selected peptides and proteins is enormous, with applications ranging from use as therapeutic vaccines, as
modulators of intracellular signaling pathways and as highly selective agents capable of recognizing unique extracellular targets. We have
been pursuing development of hybrid lipid-based carrier formulations designed to take advantage of the therapeutic benefits of peptides
selected for their ability to act in a complementary fashion with the carrier system. In this regard, it is critical to have simple and versatile
methods to promote and control the binding of diverse peptides to a broad range of carrier formulations. As demonstrated here, recombinant
proteins and synthetic peptides containing poly-histidine residues (4 to 10) can be specifically bound to liposomes containing a metal-ion-
chelating lipid, DOGS-NTA-Ni. The potential of this approach is demonstrated using two functional peptides, AntpHD-Cw3 (applications for
vaccine production) and AHNP (specificity for Her-2 expressing cells).
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1. Introduction
Hybrid delivery systems contain two or more compo-
nents; each selected to achieve a form of targeted delivery
but combined into a single formulation. Importantly, neither
delivery system alone can achieve what the combined
formulation can. This is best illustrated in our recent studies
with AntpHD-Cw3 recombinant peptide. This peptide com-
prises the homeodomain of Antennapedia (AntpHD), a
protein which is able to spontaneously cross cell membranes
to deliver a cytotoxic T lymphocyte (CTL) epitope, Cw3 to
the MHC class I presentation pathway and to prime cyto-
toxic T cells [1,2]. This protein delivery system, on its own,
has proven to be of little value in vivo because of sensitivity
to protease degradation and inefficient access to the antigen
presenting cells (APCs) of the immune system. We pro-
posed and demonstrated that a liposomal formulation of the
AntpHD-Cw3 recombinant peptide would overcome these
difficulties by protecting the peptide and by delivering the
peptide more efficiently to the appropriate APCs. In brief,
the liposomal delivery system was used to deliver a peptide
delivery system, and the combined delivery system has been
termed a hybrid formulation (Fig. 1).
Having considered this achievement, one can envision a
number of variations to this novel strategy. One recognized
variant would include the use of therapeutically active
antibodies attached to a liposomal drug formulation. The
potential to use liposomes as carriers for delivering phar-
maceutically active agents is well recognized [3,4] and the
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goal of targeting liposome through use of monoclonal anti-
bodies to achieve improved selectivity and delivery of drugs
to defined cell populations is still being actively pursued [5].
However, recent successes with monoclonal antibodies
exhibiting therapeutic activity when administered intrave-
nously [6], suggest the possibility of using these antibodies
in combination with lipid-based carriers to prepare hybrid
delivery systems as opposed to a targeted formulation. This
may be viewed more as a conceptual distinction; however,
the design features being pursued would be quite unique. A
practical application of this idea would include development
of Herceptin [7] or Rituximab [8] attached to a liposomal
anticancer drug in a manner that could improve the ther-
apeutic activity of the antibody as well as the liposomal
drug. A rationale for Herceptin/liposomal doxorubicin has
been proposed by our research team based on the known
synergistic action of Herceptin and doxorubicin when com-
bined to treat breast cancer [9]. Although clinically promis-
ing, the combination of Herceptin and doxorubicin engen-
ders a significant increase in cardiac toxicity. A hybrid
formulation comprising Herceptin with liposomal doxoru-
bicin should enhance the delivery of the antibody to the
disease site population and, provided its bioavailability and
activity have not been compromised, the combination of
liposomal doxorubicin and Herceptin should be enhanced
compared to either agent alone or administered as an un-
linked combination. The latter approach should be consid-
ered as distinct from the tactics of others who have defined
methods for the covalent attachment of proteins to lip-
osomes with the specific aim of targeting the liposomes to
a defined cell population. This approach has been elegantly
demonstrated by Park et al. [30] for liposomes with anti-
Her-2 antibodies covalently coupled to liposomes.
Several therapeutically active peptides have been de-
scribed and we have considered a few of these for develop-
ment of the hybrid formulations described here. These
include RGD peptides, the integrin– ligand interactions
inhibitors [10] that can be used to probe integrin functions
in various biological systems; the AHNP peptide derived
from the anti-p185Her-2/neu antibody (Herceptin) [11], shown
to be effective in limiting tumor growth in vivo; and AntpHD
peptide vector demonstrated to be able to deliver CTL epitope
to APC and induce CTL responses for vaccine development
[2].
Our enthusiasm for the potential of hybrid protein/lipid
delivery systems has led us to reconsider standard methods
of combining peptides with lipid-based delivery systems. In
particular, covalent and non-covalent means of attaching
Fig. 1. Design of hybrid delivery systems using liposomes and peptides. The distinct roles of liposomes and peptides can be combined for various applications
including vaccine development (A) and targeted drug delivery (B).
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peptides to lipid structures have proven to be reasonably
inefficient and the methods must be customized to the
protein/peptide of interest [12,13]. This is a time-consuming
and frustrating exercise that is often difficult to consider
when working with materials that are available in small
quantities and are expensive to produce. Our experience
with synthetic peptides and recombinant proteins, however,
led us to an interesting solution that could provide versatility
and efficiency in preparing hybrid carriers as well as
offering the potential to easily control binding and dissoci-
ation parameters.
It is well established that electron-rich ligands such as
histidine, tryptophane or cysteine bind with relatively high
affinity to electropositive transition metals, including Co2 +,
Ni2 +, Cu2 + and Zn2 +. This observation has been exploited to
allow the selective purification of recombinant proteins that
have been engineered to contain a stretch of His residues,
typically at the N- or C-terminus [1,14], a method commonly
referred to as immobilized metal affinity chromatography
(IMAC). The presence of 4 to 10 contiguous histidine
residues provides a tag that can stably bind a metal chelate
affinity column and withstand extensive washing to remove
non-specifically bound proteins. Recently, metal-ion-chelat-
ing lipids have been synthesized and used to study proteins,
prepared with a His-tag, immobilized on a lipid monolayer.
These previous studies were designed to determine structural
information on diverse proteins including membrane proteins
and to study the interactions of enzymes with their ligands by
crystallography [15–17]. The present manuscript describes a
new technology to improve and control the association of
peptides to liposomes that exploits the affinity between
histidine-tagged peptides and liposomes containing metal-
chelating lipids. In particular, two peptides, (His)10-
AntpHD-Cw3 and (His)4-AHNP were used to demonstrate
rapid and efficient attachment of the peptides to liposomes.
Importantly, it has also been shown that both peptides
conserved their biological functions.
2. Results and discussion
2.1. AntpHD-Cw3-liposome hybrid prepared using lip-
osome incorporated DOGS-NTA-Ni lipid
AntpHD-Cw3, a 128-amino acid peptide was prepared
with a 10-histidine sequence tag at its amino terminal end.
We have previously shown that incorporation of this peptide
into liposomes (DOPC/Chol) achieved less than 50% asso-
ciation efficiency and this was reduced to 35% when those
liposomes had surface-associated polyethylene glycol. The
incorporation of this recombinant peptide is due primarily to
its hydrophobicity, an attribute that is linked to its ability to
spontaneously cross plasma membranes [1]. The studies
illustrated in Fig. 2 were designed to determine whether the
incorporation efficiency of this recombinant peptide could
be improved when 10 mol% of DOGS-NTA-Ni lipid was
incorporated into DOPC/Chol liposomes. This liposome
was also prepared with 5 mol% of DSPE-PEG2000, a lipid
that inhibits non-specific association of the peptide with the
liposomes. The elution profile shown in panel A clearly
indicates that close to 100% of the added His-tagged protein
could be associated with these liposomes, and peptide-to-
lipid ratios of 20 Ag/Amol were obtained (Fig. 2A). In the
absence of the nickel-chelated lipid (Fig. 2B), peptide-to-
lipid ratios of 6 Ag/Amol were obtained, a result that is
consistent with our previous data demonstrating spontane-
ous association of AntpHD-Cw3 with liposomes. Although
not shown here, we established that 10 mol% DOGS-NTA-
Ni provided optimal AntpHD-Cw3 binding attributes
(recombinant peptide binding in the absence of aggregation)
and using this concentration, the influence of the initial
AntpHD-Cw3 peptide-to-lipid ratio on binding efficiency
was characterized. These results, shown in Fig. 2C, dem-
onstrate that saturation occurs around 50 Ag AntpHD-Cw3/
Amol liposomal lipid. Increasing the initial ratio from 60 to
80 Ag AntpHD-Cw3 per Amol total lipid caused a decrease
in the coupling efficiency from 80% to 65%, respectively. In
comparison, liposomes made in the absence of the nickel-
chelated lipid exhibited an efficiency of association of 50%
at the lower (20, 40 and 60 Ag) AntpHD-Cw3 to lipid
starting ratio. This efficiency decreased to 40% when the
initial ratio of AntpHD-Cw3 to lipid was 80 Ag/Amol. It is
important to note that the specificity of the binding reaction
between the His-tagged AntpHD-Cw3 peptide and DOGS-
NTA-Ni liposomes was confirmed by demonstrating that the
binding reaction (as opposed to incorporation occurring as a
consequence of hydrophobic interaction) could be inhibited
in the presence of 166 mM imidazole (result not shown). In
addition, it should be noted that the use of a 10-histidine tag
promoted liposome–liposome cross-linking in the absence
of PEG-modified lipids (Table 1). This could be explained
by suggesting that the stretch of 10 histidine residues would
be sufficient to bind more than one DOGS-NTA-Ni lip-
osome. Alternatively, cross-linking could be due to the
presence of multiple functional groups on the peptide such
that binding due to His tag interactions could occur for one
liposome while a second liposome could interact with the
peptide through hydrophobic interactions. Others have
demonstrated that the presence of PEG polymers inhibit
surface reactions between liposomes, and can thus be used
to prevent aggregation [18].
2.2. Biological activity of (His)10-AntpHD-Cw3-liposome
hybrid
The results presented so far demonstrate that the AntpHD-
Cw3 peptide delivery system can be easily prepared using
liposomes with incorporated DOGS-NTA-Ni lipids. The
procedure is rapid, simple and reproducible; however, it is
important to demonstrate the protein delivery and liposome
delivery attributes of the resulting formulation. Specifically,
liposome-mediated delivery to APCs and subsequent
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AntpHD-mediated delivery of the Cw3 CTL epitope to the
appropriate processing pathway should stimulate CTL. We
demonstrated in a previous study that liposome-associated
AntpHD-Cw3 formulations are first endocytosed by cells
then trafficked through the proteasome [2]. To achieve Cw3/
MHC class-I presentation to CD8+ T cells, APCs must
internalize the hybrid formulation and following intracellular
dissociation of the AntpHD-Cw3 peptide and delivery into
the cytosol, the peptide must then enter the class I processing
pathway [19]. We demonstrated this pathway for hybrid
formulations prepared through methods that rely on sponta-
neous association of the AntpHD-Cw3 peptide with lip-
osomes. Similarly, we assess the biological activity of
formulations prepared here following immunization of mice
with the peptide associated with either DOPC/DOGS-NTA-
Ni/Chol/DSPE-PEG2000 or DOPC/Chol/DSPE-PEG2000 lip-
osomes. Results from Elispot assays (Fig. 3), which monitor
immune system stimulation by measuring the frequency of
splenocytes secreting IFNg, shows that one immunization
with 50 Ag AntpHD-Cw3 formulated with DOGS-NTA-Ni
liposomes was able to stimulate the immune system specif-
ically against Cw3 peptide. The frequency of splenocytes
secreting IFNg, obtained with injection of the peptide in this
formulation was higher than the frequency obtained using the
formulation prepared through spontaneous peptide associa-
tion, however, this difference was not statistically significant.
It is believed that only the antigen that is stably associated
with liposomes will be able to elicit antigen-specific T cell
response [20,21]. We have previously shown that AntpHD-
Table 1
Size of the formulation in the presence of various mol% of DSPE-PEG,
before and after addition of AntpHD-Cw3
DSPE-PEG (%) Size after
extrusion (nm)
Size after +
AntpHD-Cw3
0 118F 15 >1 Am
2 120F 21 >1 Am
5 126F 22 174F 24 nm
Fig. 2. Association of AntpHD-Cw3 peptide with liposomes. DOPC/DOGS-NTA-Ni (10%)/Cho/DSPE-PEG (A) and DOPC/Chol/DSPE-PEG (B) liposomes
(10 Amol) were incubated with 200 Ag AntpHD-Cw3. Subsequently, free peptide was separated from the associated peptide using size exclusion
chromatography and the amount of peptide (.) and lipid (5) was determined for each fraction as described in Experimental protocols. The results presented are
from a single representative experiment. The association of AntpHD-Cw3 as a function of initial peptide-to-liposome ratio is shown in panel C. DOPC/Chol/
DSPE-PEG liposomes containing 0% (5) and 10% (n) DOGS-NTA-Ni were incubated with AntpHD-Cw3 at various peptide-to-liposome ratios for 30 min at
room temperature. The amount of peptide bound was determined after the incubation period as described in Experimental protocols. Data presented represent
averaged results obtained from three liposome preparations F S.E.
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Cw3, in the absence of liposome, is unable to induce a T cell
response [2]. The approach presented here allows for more
efficient association of the transducing peptide than can be
obtained through spontaneous binding and more efficient
coupling allows a higher protein-to-lipid ratio to be achieved.
Thus, a greater number of peptides are attached per liposome
when using liposomes prepared with DOGS-NTA-Ni. This,
in turn, will allow more peptide to be delivered with each
liposome taken into the target cell population.
2.3. Coupling of a synthetic 4-histidine tagged peptide,
AHNP
The results outlined above demonstrate improved cou-
pling efficiency for a hydrophobic peptide that can sponta-
neously associate with liposomes, albeit at a significantly
reduced efficiency, even in the absence of a coupling
method. It is, however, appropriate to consider whether this
procedure can be applied more generally, thus we assessed
this approach using a synthetic nanomere peptide, AHNP
containing a 4-histidine residue tag. AHNP is a peptidomi-
metic of Herceptin, an antibody with proven clinical activity
against Her-2 overexpressing cancers [11]. The results,
presented in Fig. 4, demonstrate rapid and efficient binding
of the synthetic peptide to achieve levels of 25–30 Ag of
AHNP per Amol lipid. The efficiency of the coupling
reaction was >60% and the dependency of coupling on
the DOGS-NTA-Ni lipid was clear. In the absence of
DOGS-NTA-Ni lipid, the amount of peptide bound to the
DSPC/Chol liposomes at room temperature (RT) (22 jC)
was insignificant, even after a 19 h incubation time. If those
liposomes were prepared with 5 mol% DOGS-NTA-Ni,
coupling was observed in less then 15 min and the rate of
coupling was not substantially affected when the incubation
temperature increased from 20 to 37 jC. Furthermore, the
results summarized in Fig. 4 also demonstrate that addition
of 5 mol% of DSPE-PEG2000 caused a slight, but measur-
able, change in the rate of binding (the maximum level of
association was reached after 1 h as opposed to >10 min in
the absence of the PEG-modified lipid), but the efficiency of
incorporation did not change.
Fig. 5A demonstrates how coupling of the His-tagged
AHNP peptide was affected by the initial peptide-to-lip-
osome ratio and mol% of DOGS-NTA-Ni lipid used when
preparing the liposomes. In the absence of the metal-
chelating lipid, the level of peptide association was less
than 4 Ag of AHNP per Amol lipid, a level observed when
the initial peptide-to-lipid ratio was 80 Ag/Amol. For lip-
osomes prepared with a defined amount of the DOGS-NTA-
Ni lipid, AHNP association increased linearly as a function
of increased AHNP levels added. Further, the level of
AHNP association increased at any given peptide concen-
tration as the mol% of DOGS-NTA-Ni incorporated in the
liposomes was increased. It should be noted that these
formulations could not be prepared with 10 mol% DOGS-
NTA-Ni due to a DOGS-NTA-Ni-mediated aggregation
reaction (data not shown). However, when using 5 mol%
of the Ni-modified lipid, there was no aggregation observed
in the absence of PEG-modified lipids. This was unlike the
observations with His-tagged AntpHD-Cw3, and this may
be due to the number of histidine residues attached to the
peptide and/or the fact that AntpHD-Cw3 has hydrophobic
regions. The study summarized in Fig. 5B indicates that
complete inhibition of AHNP binding to the DOGS-NTA-
Ni liposomes could be achieved using 60 mM imidazole. As
noted earlier, 166 mM imidazole was required to inhibit the
Fig. 4. Time course of His-AHNP coupling to DSPC/Chol liposomes (E),
DSPC/Chol/DOGS-NTA-Ni (5%) liposomes (n,.), and DSPC/DOGS-
NTA-Ni (5%)/Chol/DSPE-PEG2000 (5%) (z). Liposomes were incubated
with His-AHNP at a peptide-to-liposome ratio of 50 Ag/Amol. Unbound
peptide was removed as described in Experimental protocols to determine
the amount of peptide bound. Results presented are single determinations
from a representative experiment.
Fig. 3. Frequency of Cw3-specific T cells as determined by an IFNg Elispot
assay. BALB/c mice were immunized subcutaneously on day 0 with 50 Ag
AntpHD-Cw3 either in DOPC/Chol/DSPE-PEG or in DOPC/Chol/DSPE-
PEG/DOGS-NTA-Ni (10%) liposomes. On day 7, spleen cells from
individual mice were stimulated for 36 h with 10 AM Cw3 (170–179) and
then assayed for the number of Cw3-specific cells as described in
Experimental protocols. Data presented represent averaged results obtained
from six mice F S.E.
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association of the 10 His-tagged AntpHD-Cw3 peptide to
liposomes, and at an imidazole concentration of 60 mM,
very weak inhibition was observed. Although not conclu-
sive, these inhibition data suggest that binding stability may
increase as the length of the His-tag used increases.
Fig. 6 illustrates that AHNP coupled to liposomes
through the DOGS-NTA-Ni lipid can bind SKBR3 breast
cancer cells, a cell line known to overexpress Her-2/neu as a
consequence of gene amplification. AHNP-mediated bind-
ing of liposomes to cells is substantially greater than com-
parable formulations prepared without the peptide.
In considering the utility of this coupling approach to
prepare hybrid delivery systems there are studies suggest-
ing that nickel compounds are potentially carcinogenic
[22] and, therefore, it is unlikely that the DOGS-NTA-Ni
will be of value when considering the development of
hybrid liposome–peptide delivery systems for human use.
Having stated this, it is worth noting that acute toxicity
studies in mice given three weekly i.v. or s.c. administered
doses of 4 Amol DOPC/DOGS-NTA-Ni (10%)/Chol/DSPE-
PEG or 3.3 Amol DSPC/DOGS-NTA-Ni (5%)/Chol i.v.
resulted in no overt signs of toxicity over a 30-day time
period after the third injection (results not shown). In
addition, preliminary pharmacokinetic analysis of the
DOGS-NTA-Ni suggested that there was little in the way
of a detectable immune response to this lipid (results not
shown). This does not suggest, however, that formulations
with attached peptides are not immunogenic. Assuming
that an alternative to DOGS-NTA-Ni will have to be
identified for long-term safety reasons, it is important to
understand that other transition metals such as cobalt and
copper have available coordination sites and each of these
coordination sites has the capacity to interact with elec-
tron-rich ligands such as histidine, tryptophane or cysteine
residues [23]. While the interactions of these residues with
metal ions may be relatively weak, increasing the number
of amino acids used to define the affinity tag will increase
binding strength. We believe that the data summarized in
this report provides ‘‘proof-of-principle’’ support to the
concept of using liposomes with DOGS-NTA-Ni to couple
peptides with histidine tags. We are now exploring the use
of other, perhaps safer, metal-ion-chelating lipids as alter-
natives to DOGS-NTA-Ni [24]. We believe that this ap-
proach, in general, is particularly suitable for preparation
and characterization of recombinant and synthetic peptides
engineered to have an affinity tag. This is a promising
approach because of its simplicity, efficiency and the
potential to control binding and dissociation of the pep-
tides in a well-defined manner. In addition, since chemical
modification of the peptide is not required after isolation, it
is more likely that the functional properties of the peptide
will be maintained, thus retaining the full therapeutic
potential of each component of the hybrid formulations
prepared using this approach.
Fig. 6. Binding of AHNP associated to DOGS-NTA-Ni liposomes to
SKBR3 cells. SKBR3 cells (106) were incubated with 1 Amol of each
indicated liposome formulation at 4 jC. After 4 h incubation, cells were
washed, counted and liposomal lipid quantified using scintillation counting.
Fig. 5. Coupling of His-AHNP as a function of initial peptide-to-liposome
ratio and binding specificity. (A) DSPC/Chol liposomes (1 Amol)
containing 0% (n), 1% (.), 2% (E), and 5% (z) DOGS-NTA-Ni were
incubated with various amounts of His-AHNP for 19 h at room
temperature. The amount of peptide bound was determined after the
incubation period as described in Experimental protocols. (B) Inhibition of
AHNP binding to DSPC/Chol liposomes containing the indicated amount
of DOGS-NTA-Ni lipid at 50 Ag/Amol initial ratio. In the presence (E) or
in the absence (n) of 60 mM imidazole.
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3. Experimental protocols
3.1. Materials
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) lipid
was purchased from Northern Lipids (Vancouver, Canada).
1,2-Distearoyl-sn-glycero-3-phosphatidylethanolamine-n-
[poly(ethylene glycol)2000] (DSPE-PEG2000), 1,2-dioleoyl-
sn-glycero-3-{[n(5-amino-1-carboxypentyl)iminodiacetic
acid]succinyl} (Nickel Salt) (DOGS-NTA-Ni) and 1,2-dis-
tearoyl-sn-glycero-3-phosphocholine (DSPC) were pur-
chased from Avanti Polar Lipids (Birmingham, AL). CHE
[3H] cholesterol-hexadecyl ether was purchased from Amer-
sham (Piscataway, NJ) (1 mCi/ml). Cholesterol was obtained
from Sigma (St. Louis, MO). Pico-Fluor-40 scintillation
cocktail was obtained from Canberra-Packard Canada (Mis-
sasauga, ON). RPMI and DMEM media were purchased
from Stem Cell Technologies (Vancouver, Canada). Elispot,
multiscreen IP clear plates were obtained from Millipore
(Bedford, MA). MicroBCA protein assay kit was obtained
from Pierce (Rockford, IL). Centrifuge device (Microcon-
30) was obtained from Millipore (Nepean, ON). Biogel 1.5
and 15 m were obtained from Bio-Rad (Hercules, CA).
Peptide 170–179 HLA-Cw3 (RYLKNGKETL) and the
cyclic peptide His-AHNP (HHHHFCDGFYACYMDV)
were synthesized by the Biotechnology Laboratory (UBC,
Vancouver, Canada).
3.2. Animals
BALB/c (H2d) mice were obtained from the joint animal
facility at the British Columbia Cancer Research Centre
(Vancouver, Canada). All animal studies were completed
using protocols that were approved by the Institution
Animal Care committee and the methods used were con-
sistent with the current guidelines of the Canadian Council
of Animal Care.
3.3. Cell culture
SKBR3 cells were cultured in DMEM medium supple-
mented with 10% FBS, L-glutamine (1%), and penicillin/
streptomycin (1%) at 37 jC in a humidified incubator with
5% CO2.
3.4. AntpHD-Cw3 gene construction and synthesis
AntpHD-Cw3 fusogenic peptide initially cloned in
pAH61S plasmid [25] was sub-cloned into the pET19
(Novagen, Inc., Madison, WI) between NdeI and BamHI
under the control of a T7 promoter. The peptide was
expressed as a fusion peptide containing 10 histidine resi-
dues plus 13-amino acid linker attached to its amino
terminus. For peptide expression, Escherichia coli strain
BL21 (DE3) Lys was used, it contains the T7 RNA
polymerase gene under control of lac promoter [26]. Peptide
was purified as previously described [1], by nickel-chelate
affinity resin according to the recommendations of the
supplier (Qiagen, Chatsworth, CA). The eluted fractions
were analyzed by SDS-PAGE on 15% gels and Coomassie
blue staining. Purity was assessed at 80–90%. Before
incubation with liposomes, the peptide was dialyzed against
50 mM NaH2PO4, 400 mM NaCl, pH 8 buffer in order to
remove the imidazole, which might interfere with the
peptide association with DOPC/DOG-NTA-NI/CHOL/
DSPE-PEG2000 liposomes.
3.5. Liposome preparation
Liposomes were prepared using the method described by
Hope et al. [27]. Lipid mixtures used were DOPC/Chol,
DOPC/Chol/DSPE-PEG2000, DOPC/DOGS-NTA-Ni/Chol,
DOPC/DOGS-NTA-Ni/Chol/DSPE-PEG2000, DSPC/Chol,
DSPC/DOGS-NTA-Ni/Chol and DSPC/DOGS-NTA-Ni/
Chol/DSPE-PEG2000 at the indicated mol% ratio. The lipids
were dissolved in chloroform and trace levels of [3H]
cholesteryl hexadecyl ether (1–5 ACi/100 Amol total lipid)
were added as a non-exchangeable and non-metabolizable
liposomal lipid marker [28]. A lipid film was formed
following removal of excess solvents under a stream of
nitrogen gas. The lipid film was then placed under high
vacuum for at least 3 h to remove all residual solvent before
hydration either with HBS (100 mM HEPES; pH 7.4, 150
mM NaCl) for liposomes used for AHNP peptide or
phosphate buffer (50 mM NaH2PO4, 400 mM NaCl,
pH8) for liposomes used for AntpHD-Cw3 peptide. The
resulting multilamellar vesicles were subjected to five
freeze–thaw cycles [29] and then extrusion (10 times)
through 100 nm pore size polycarbonate filters (Nucleo-
pore) using an extrusion device (Northern Lipids). Lip-
osome size was determined by quasi-elastic light scattering
using Nicomp submicron particle size analyzer. All lip-
osomal preparations exhibited average diameters of 100–
120F 25 nm.
3.6. AntpHD-Cw3 conjugation to liposomes
Two hundred micrograms of AntpHD-Cw3 dialyzed
against 50 mM NaH2PO4, 400 mM NaCl, pH8 buffer,
was incubated with 10 Amol liposomes (v/v) for 30 min
at RT under rotary shaking. The mixture was then loaded
on a Biogel A 1.5 m chromatography column in order to
remove the free peptide from peptide that was incorpo-
rated into the liposome. The peptide/liposome ratio was
determined by quantifying liposomal lipid using [3H]
CHE. Radioactivity was measured by liquid scintillation
counting on the Canberra-Packard Scintillation h counter
(1900 TR Tri Carb), using Pico-fluor 40 scintillation
cocktail. The peptide was quantified using micro-BCA
protein assay kit, after dissolving the liposomes in 0.5%
Triton X-100. BSA was used as the standard for this
analysis.
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3.7. AHNP peptide conjugation to liposomes
In the conjugation reaction, (His)4-AHNP (10–80 Ag)
was incubated with liposomes (1 Amol) in a total volume of
50 Al HBS (pH 7.4) at 37 jC or at room temperature for the
indicated time periods as specified in each experiment. His-
peptide conjugation to liposomes was quantified indirectly
by measuring the amount of free peptide at the end of the
conjugation reaction. Unbound peptide was separated using
the Microcon-30 centrifuge device. Before centrifugation,
the liposome–peptide mixture was diluted to a final volume
of 250 Al in HBS. After centrifugation for 13 min at
12,000 g, 20 Al of the filtrate was assayed for free peptide
content using the micro-BCA assay. The amount of peptide
bound to liposomes was determined by subtracting the
amount of free peptide from the total amount used. This
indirect quantification method of His-peptide binding to
liposomes was compared with and yielded the same result
as the direct method where liposome-bound peptide was
directly quantified using the micro-BCA assay after sepa-
ration of free peptide by size exclusion chromatography
using Biogel A 15 m gel matrix (results not shown). For
binding inhibition assay, 3 Al of a 1 M imidazole solution
was added to the reaction mixture before the addition of
liposomes.
3.8. Cell binding experiments
The SKBR3 cell line, positive for HER-2/neu, was used
for liposome binding experiments. On the day of the experi-
ment, the cells were harvested using trypsin/EDTA and then
washed once using DMEM complete medium. One million
cells were incubated at 4 jC for 4 h in 0.5 ml medium
containing 1 mM of liposomes. To remove unbound lip-
osomes, the cells were washed three times using 3.5 ml of
PBS and centrifuged for 5 min at 1500 rpm for each wash.
The cells recovered after washing were then counted using 5
ml of Pico-Fluor 40 scintillation cocktail and using a
Beckman LS 3801 scintillation counter.
3.9. Immunization
Groups of BALB/c mice (six per group), 6–8 weeks of
age, were immunized s.c. once. On day 7, spleens were
harvested and the immune response was monitored using an
Elispot as described bellow.
3.10. Elispot
We have used the same the Elispot assay protocol
described by Chikh et al. [2]. Briefly, Elispot plates (Multi-
screen-IP Clear plates, Millipore) were coated overnight at 4
jC with capture anti-INFg antibody (2 Ag/ml) (clone R4-
6A2) (Pharmingen). The plates were then blocked with 1%
BSA in PBS for 2 h at RT. After three washes, responder
cells in RPMI medium supplemented with 10% ConA
supernatant containing TCGF (T cell growth factors), 10%
FCS, 1% glutamine, 1% penicillin/streptomycin and 5
10 5 M h-2-ME (mercaptoethanol) were added to the wells
along with 5 105 irradiated syngeneic feeder cells. Cells
were incubated for 36 h in the presence or absence of 10 AM
of Cw3 (170–179) peptide. After culture, the plates were
washed and biotinylated anti-INFg detection antibody
(clone XMG1.2) (Pharmingen) was added (1 Ag/ml) and
the plates were then incubated for 1 h at RT. Spots
developed following addition of freshly prepared HRP
diluted 1:2000 in PBS/Tween containing 1% BSA, followed
by repeated (5) washes with PBS/Tween and addition of
200 Al of HRP substrate (Opti-4CN substrate kit, Bio-Rad).
The frequency of peptide-specific T cells was calculated
based on the percentage of cells present in the responding
population.
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